PET scan to monitor immunotherapy in advanced liver cancer
Part of Cancer clinical trials.
This trial uses a special PET scan (68Ga-grazytracer) to see how well immunotherapy is working in people with advanced liver or bile duct cancer. The goal is to find a better way to monitor treatment response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of advanced liver or bile duct cancer and your doctor plans to treat you with immunotherapy.
- You are between 18 and 75 years old.
- You are in generally good health, with an expected survival of more than 6 months.
- You do not have serious health problems like severe heart or lung failure, severe bone marrow suppression, or severe liver or kidney problems.
- You are not pregnant, possibly pregnant, or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special PET scan called 68Ga-grazytracer to see how well immunotherapy is working in people with stomach, colon, or other gastrointestinal cancers. The goal is to find out if this scan can help doctors track your response to treatment.
This trial uses a special PET scan (68Ga-grazytracer) to see how well immunotherapy is working for pancreatic cancer. It may help your doctor understand if your treatment is effective.
This trial uses a special PET scan (68Ga-FAPI) to see how well systemic therapy is working in people with advanced liver cancer that can't be removed by surgery. The goal is to find a better way to measure treatment effectiveness.
This trial tests a special PET scan (68Ga-grazytracer) to see if it can predict early whether immunotherapy is working in people with lung cancer that can be surgically removed. If successful, this scan could help doctors tailor treatment sooner.
This trial uses a special PET scan called 68Ga-grazytracer to see how well your soft tissue sarcoma responds to immunotherapy treatment. It may help doctors understand if the treatment is working.
This trial uses a special PET scan (68Ga-grazytracer) to find out whether growth seen on scans after immunotherapy is real cancer growth or a harmless reaction called pseudoprogression. It helps doctors decide if your treatment is working.
Hear when a new Hepatobiliary Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.